See more : Energy and Environmental Services, Inc. (EESE) Income Statement Analysis – Financial Results
Complete financial analysis of Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. (688076.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sinopep-Allsino Bio Pharmaceutical Co.,Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Hailun Piano Co.,Ltd. (300329.SZ) Income Statement Analysis – Financial Results
- Cryomass Technologies Inc. (CRYM) Income Statement Analysis – Financial Results
- Tytan Holdings, Inc. (TYTN) Income Statement Analysis – Financial Results
- Srisawad Capital 1969 Public Company Limited (SCAP.BK) Income Statement Analysis – Financial Results
- Eastern Media International Corporation (2614.TW) Income Statement Analysis – Financial Results
Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. (688076.SS)
About Sinopep-Allsino Bio Pharmaceutical Co.,Ltd.
Sinopep-Allsino Bio Pharmaceutical Co.,Ltd., a biomedical company, engages in the research and development, production, sale, and technical service of peptides and small molecule drugs in China. The company offers formulations, such as thymalfasin products for injection, eptifibatide injections, alogliptin benzoate tablets, and oseltamivir phosphate capsules; APIs and intermediates; and drugs for type 2 diabetes and obesity, and coronavirus. It also provides pharmaceutical research, clinical, and registration services of drugs; and undertakes CDMO/CMO projects of small molecule chemical API and intermediates. The company was founded in 2009 and is headquartered in Hangzhou, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.03B | 651.29M | 643.87M | 566.87M | 371.53M | 255.53M | 228.87M | 8.02M | 8.78M | 0.00 | 0.00 |
| Cost of Revenue | 444.27M | 276.32M | 284.87M | 237.16M | 173.25M | 101.99M | 87.82M | 13.63M | 7.53M | 593.70K | 425.91K |
| Gross Profit | 582.08M | 374.97M | 358.99M | 329.72M | 198.28M | 153.54M | 141.04M | -5.61M | 1.25M | -593.70K | -425.91K |
| Gross Profit Ratio | 56.71% | 57.57% | 55.76% | 58.16% | 53.37% | 60.09% | 61.63% | -69.91% | 14.21% | 0.00% | 0.00% |
| Research & Development | 124.89M | 69.47M | 63.09M | 60.53M | 46.50M | 35.12M | 17.44M | 15.52M | 0.00 | 3.57M | 1.54M |
| General & Administrative | 76.34M | 53.14M | 58.26M | 39.79M | 29.11M | 19.76M | 12.90M | 71.49M | 26.17M | 20.37M | 14.02M |
| Selling & Marketing | 42.06M | 34.97M | 12.59M | 11.55M | 8.86M | 3.09M | 1.53M | 853.11K | 509.30K | 169.13K | 105.80K |
| SG&A | 273.34M | 88.11M | 70.84M | 51.34M | 37.97M | 22.85M | 14.43M | 65.06M | 26.68M | 20.54M | 14.12M |
| Other Expenses | 1.39M | 97.96M | 80.21M | 47.64M | 51.83M | -95.20K | 418.57K | -96.56K | 203.49K | 735.56K | 2.86M |
| Operating Expenses | 399.62M | 255.54M | 214.14M | 159.51M | 136.29M | 112.00M | 73.28M | 65.15M | 26.68M | 20.54M | 14.12M |
| Cost & Expenses | 843.88M | 531.86M | 499.02M | 396.66M | 309.54M | 213.99M | 161.10M | 78.79M | 34.21M | 20.54M | 14.12M |
| Interest Income | 5.87M | 8.58M | 5.29M | 736.82K | 600.03K | 440.94K | 192.77K | 4.54M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 16.09M | 9.26M | 6.12M | 11.63M | 7.16M | 9.39M | 6.71M | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 135.55M | 104.68M | 89.02M | 77.12M | 46.34M | 25.90M | 18.90M | 10.75M | 9.70M | 9.45M | 3.41M |
| EBITDA | 324.76M | 237.28M | 221.02M | 236.27M | 107.59M | 60.13M | 82.56M | -58.80M | -15.73M | -10.93M | -10.80M |
| EBITDA Ratio | 31.64% | 37.63% | 36.29% | 42.71% | 29.46% | 26.28% | 37.68% | -748.04% | -174.09% | 0.00% | 0.00% |
| Operating Income | 189.67M | 124.85M | 128.31M | 143.82M | 67.81M | 31.44M | 56.60M | -70.76M | -30.36M | -25.89M | -16.50M |
| Operating Income Ratio | 18.48% | 19.17% | 19.93% | 25.37% | 18.25% | 12.30% | 24.73% | -882.04% | -345.87% | 0.00% | 0.00% |
| Total Other Income/Expenses | -16.54M | -1.69M | -2.58M | 2.75M | -14.40M | -95.20K | 418.57K | -4.04M | 203.49K | 735.56K | 2.86M |
| Income Before Tax | 173.13M | 123.16M | 125.73M | 146.56M | 53.41M | 31.34M | 57.01M | -74.80M | -30.15M | -25.16M | -13.64M |
| Income Before Tax Ratio | 16.87% | 18.91% | 19.53% | 25.85% | 14.38% | 12.27% | 24.91% | -932.34% | -343.55% | 0.00% | 0.00% |
| Income Tax Expense | 7.67M | 387.71K | 16.92M | 26.53M | 8.61M | -13.34M | 15.08M | 5.00 | 5.38M | 5.19M | 767.20K |
| Net Income | 162.94M | 129.11M | 115.39M | 123.44M | 48.61M | 43.91M | 41.93M | -74.80M | -30.15M | -25.16M | -13.64M |
| Net Income Ratio | 15.88% | 19.82% | 17.92% | 21.78% | 13.08% | 17.18% | 18.32% | -932.34% | -343.55% | 0.00% | 0.00% |
| EPS | 0.76 | 0.61 | 0.54 | 0.58 | 0.23 | 0.32 | 0.37 | -0.35 | -0.60 | -0.50 | -0.27 |
| EPS Diluted | 0.76 | 0.61 | 0.54 | 0.58 | 0.23 | 0.32 | 0.37 | -0.35 | -0.60 | -0.50 | -0.27 |
| Weighted Avg Shares Out | 214.39M | 213.18M | 213.18M | 213.18M | 213.18M | 137.21M | 113.32M | 213.18M | 50.26M | 50.31M | 50.50M |
| Weighted Avg Shares Out (Dil) | 214.39M | 213.18M | 213.18M | 213.18M | 213.18M | 137.21M | 113.32M | 213.18M | 50.26M | 50.31M | 50.50M |
Source: https://incomestatements.info
Category: Stock Reports